LifeStance Health Group, Inc. (NASDAQ:LFST) Given Average Recommendation of “Moderate Buy” by Analysts

LifeStance Health Group, Inc. (NASDAQ:LFST) has received a consensus rating of “Moderate Buy” from the eleven research firms that are currently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $11.1250.

Several equities analysts recently commented on the company. JPMorgan Chase & Co. upped their price objective on LifeStance Health Group from $8.00 to $9.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. Zacks Research downgraded LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. BTIG Research boosted their target price on LifeStance Health Group from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Barclays upped their price target on LifeStance Health Group from $9.00 to $13.00 and gave the company an “overweight” rating in a research report on Tuesday, July 14th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of LifeStance Health Group in a research note on Wednesday, May 27th.

Insider Activity at LifeStance Health Group

In other LifeStance Health Group news, Director Robert Bessler sold 894,337 shares of the company’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $10.13, for a total transaction of $9,059,633.81. Following the sale, the director directly owned 539,763 shares of the company’s stock, valued at $5,467,799.19. This represents a 62.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Eric Shuey sold 243,362 shares of the stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total transaction of $1,951,763.24. Following the transaction, the director owned 867,562 shares of the company’s stock, valued at $6,957,847.24. This represents a 21.91% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 7,757,293 shares of company stock worth $64,072,101. Company insiders own 3.50% of the company’s stock.

Institutional Trading of LifeStance Health Group

A number of institutional investors have recently modified their holdings of LFST. Handelsbanken Fonder AB boosted its holdings in LifeStance Health Group by 37.0% in the 2nd quarter. Handelsbanken Fonder AB now owns 41,100 shares of the company’s stock worth $440,000 after buying an additional 11,100 shares during the period. Contravisory Investment Management Inc. bought a new stake in LifeStance Health Group during the 2nd quarter valued at $451,000. Bank of America Corp DE raised its holdings in LifeStance Health Group by 165.0% during the 1st quarter. Bank of America Corp DE now owns 1,994,027 shares of the company’s stock valued at $12,702,000 after acquiring an additional 1,241,475 shares during the period. EverSource Wealth Advisors LLC raised its holdings in LifeStance Health Group by 359.1% during the 1st quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company’s stock valued at $44,000 after acquiring an additional 5,404 shares during the period. Finally, California State Teachers Retirement System lifted its position in shares of LifeStance Health Group by 32.1% during the first quarter. California State Teachers Retirement System now owns 166,084 shares of the company’s stock worth $1,058,000 after acquiring an additional 40,402 shares in the last quarter. 85.50% of the stock is currently owned by hedge funds and other institutional investors.

LifeStance Health Group Stock Up 1.0%

LFST opened at $11.45 on Wednesday. LifeStance Health Group has a twelve month low of $3.74 and a twelve month high of $11.76. The company’s 50-day moving average price is $9.15 and its two-hundred day moving average price is $7.74. The stock has a market cap of $4.44 billion, a price-to-earnings ratio of 190.83 and a beta of 1.12. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.03. The company had revenue of $403.48 million during the quarter, compared to analyst estimates of $387.46 million. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. The company’s revenue was up 21.2% on a year-over-year basis. As a group, equities analysts expect that LifeStance Health Group will post 0.12 earnings per share for the current year.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.